A5103161119- Pharmacogenetics and Drug Metabolism
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Treatments and Mutations
- Cardiac electrophysiology and arrhythmias
- Chemistry and Chemical Engineering
- Berberine and alkaloids research
- Cancer, Hypoxia, and Metabolism
- HIV/AIDS drug development and treatment
- Colorectal Cancer Treatments and Studies
- Computational Drug Discovery Methods
- Receptor Mechanisms and Signaling
- Pesticide and Herbicide Environmental Studies
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- Fibroblast Growth Factor Research
- Chronic Myeloid Leukemia Treatments
- Eicosanoids and Hypertension Pharmacology
- Neuroendocrine Tumor Research Advances
- Inflammatory mediators and NSAID effects
- Venous Thromboembolism Diagnosis and Management
- Pancreatic and Hepatic Oncology Research
- Pharmaceutical and Antibiotic Environmental Impacts
- Biosimilars and Bioanalytical Methods
- Advanced Breast Cancer Therapies
- Phytochemistry and Biological Activities
Wenzhou Medical University
2023-2025
Apatinib, a commonly used tyrosine kinase inhibitor in cancer treatment, can cause adverse reactions such as hypertension. Hypertension, turn, increase the risk of certain cancers. The coexistence these diseases makes use combination drugs more common clinical practice, but potential interactions and regulatory mechanisms drug combinations are poorly understood. We humanized CYP2D6 mouse model to predict effect apatinib on pharmacokinetics pharmacodynamics metoprolol investigated...
The purpose of this study is to clarify the drug interaction profile aumolertinib, and influence CYP3A4 genetic polymorphism on aumolertinib metabolic characteristics. Through microsomal enzyme reactions, we screened 153 drugs identified 15 that significantly inhibited metabolism aumolertinib. Among them, telmisartan carvedilol exhibited potent inhibitory activities in rat liver microsomes (RLM) human (HLM). In vivo , pharmacokinetic parameters including AUC C max were altered when...
This study aimed to evaluate the effects of cytochrome P450 3A4 (CYP3A4) gene polymorphism and drug interaction on metabolism blonanserin. Human recombinant CYP3A4 was prepared using Bac-to-Bac baculovirus expression system. A microsomal enzyme reaction system established, drug-drug interactions were evaluated Sprague-Dawley rats. Ultra-performance liquid chromatography-tandem mass spectrometry used detect concentrations blonanserin its metabolite. Compared with wild-type CYP34A, relative...
Purpose: To investigate the effects of hepatic enzyme activity variations and CYP2B6 gene polymorphisms on in vivo vitro metabolism efavirenz. Main methods: In systems using rat human liver microsomes (RLM/HLM) were established, with studies conducted Sprague–Dawley rats. Metabolite detection was performed via LC-MS/MS. Human recombinant prepared a baculovirus-insect cell system ultracentrifugation, efavirenz serving as substrate to study kinetics. Results: Isavuconazole exhibited an IC50...
Cytochrome P450 2D6 (CYP2D6) exhibits rich genetic polymorphism, and functional changes caused by variations are the key reasons for differences in substrate drug systemic exposure. Discovering novel variants defining their enzymatic kinetic characteristics can contribute to personalized application of drugs. In this study, a data chain variant-function-structure was established through population-based sequencing, baculovirus insect cell expression,